States to pull shots from sluggish hospitals To view this email as a web page,
click here Moderna scores COVID-19 vaccine backing in Europe, setting off another major vaccination push Study: Hospitals at or near full COVID-19 ICU capacity increase by 90% over past few months UC San Diego deploys COVID-19 test vending machines for returning students Biopharma roundup—States to pull shots from sluggish hospitals Healthcare roundup—CVS expects to complete first nursing home inoculations this month Regeneron’s CEO and CSO could nab a whopping $1.4B in bonuses—if the pipeline pumps up investors Featured Story | By Eric Sagonowsky Two weeks after European regulators endorsed Pfizer and BioNTech’s COVID-19 vaccine, a second shot is getting ready for a broad rollout in the region. Moderna scored regulatory support for its vaccine, enabling health officials to expand their vaccination push amid fresh lockdowns and increases in cases. read more |
| |
|---|
|
Top Stories By Robert King A new study found a 90% increase in hospitals reaching near or full ICU bed capacity over the past few months as hospitals grapple with new surges of COVID-19. read more By Conor Hale As universities nationwide begin a new semester under the COVID-19 pandemic, the University of California, San Diego is making diagnostic screening a more ubiquitous fixture of day-to-day life by offering tests in sidewalk vending machines. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner AstraZeneca's shot is now authorized in six countries. Serum Institute won't be able to export AZ's shot for several months, CEO Adar Poonawalla said. New York and Florida told hospitals deploying COVID vaccines to pick up the pace. Meanwhile, NIAID director Anthony Fauci thinks the U.S. could soon hit 1 million vaccinations per day. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Arlene Weintraub Regeneron CEO Leonard Schleifer and CSO George Yancopoulos just won rejigged performance-pay plans that promise a combined payday of up to $1.4 billion eight years from now. But their ability to nab those bonuses will rely on Regeneron's ability to grow market share for hits like Dupixent, while also getting novel drugs out of the pipeline. read more |
|
